These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 34316024)

  • 1. Tasimelteon safely and effectively improves sleep in Smith-Magenis syndrome: a double-blind randomized trial followed by an open-label extension.
    Polymeropoulos CM; Brooks J; Czeisler EL; Fisher MA; Gibson MM; Kite K; Smieszek SP; Xiao C; Elsea SH; Birznieks G; Polymeropoulos MH
    Genet Med; 2021 Dec; 23(12):2426-2432. PubMed ID: 34316024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials.
    Lockley SW; Dressman MA; Licamele L; Xiao C; Fisher DM; Flynn-Evans EE; Hull JT; Torres R; Lavedan C; Polymeropoulos MH
    Lancet; 2015 Oct; 386(10005):1754-64. PubMed ID: 26466871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tasimelteon for the treatment of non-24-hour sleep-wake disorder.
    Neubauer DN
    Drugs Today (Barc); 2015 Jan; 51(1):29-35. PubMed ID: 25685859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylphenidate for attention-deficit/hyperactivity disorder in patients with Smith-Magenis syndrome: protocol for a series of N-of-1 trials.
    Müller AR; Zinkstok JR; Rommelse NNJ; van de Ven PM; Roes KCB; Wijburg FA; de Rooij-Askes E; Linders C; Boot E; van Eeghen AM
    Orphanet J Rare Dis; 2021 Sep; 16(1):380. PubMed ID: 34496899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tasimelteon: a melatonin receptor agonist for non-24-hour sleep-wake disorder.
    Johnsa JD; Neville MW
    Ann Pharmacother; 2014 Dec; 48(12):1636-41. PubMed ID: 25204464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tasimelteon: A Review in Non-24-Hour Sleep-Wake Disorder in Totally Blind Individuals.
    Keating GM
    CNS Drugs; 2016 May; 30(5):461-8. PubMed ID: 27003694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simulated driving performance in healthy adults after night-time administration of 20 mg tasimelteon.
    Torres R; Fisher M; Birznieks G; Polymeropoulos C; Kay GG; Xiao C; Polymeropoulos MH
    J Sleep Res; 2022 Feb; 31(1):e13430. PubMed ID: 34152055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Tasimelteon (HETLIOZ®) in the Treatment of Jet Lag Disorder Evaluated in an 8-h Phase Advance Model; a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
    Polymeropoulos CM; Mohrman MA; Keefe MS; Brzezynski JL; Wang J; Prokosch LS; Polymeropoulos VM; Xiao C; Birznieks G; Polymeropoulos MH
    Front Neurol; 2020; 11():611. PubMed ID: 32754110
    [No Abstract]   [Full Text] [Related]  

  • 9. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials.
    Rajaratnam SM; Polymeropoulos MH; Fisher DM; Roth T; Scott C; Birznieks G; Klerman EB
    Lancet; 2009 Feb; 373(9662):482-91. PubMed ID: 19054552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sleep in children with Smith-Magenis syndrome: a case-control actigraphy study.
    Trickett J; Oliver C; Heald M; Denyer H; Surtees A; Clarkson E; Gringras P; Richards C
    Sleep; 2020 Apr; 43(4):. PubMed ID: 31630201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tasimelteon for treating non-24-h sleep-wake rhythm disorder.
    Nishimon S; Nishimon M; Nishino S
    Expert Opin Pharmacother; 2019 Jun; 20(9):1065-1073. PubMed ID: 30990759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absolute Bioavailability of Tasimelteon.
    Torres R; Dressman MA; Kramer WG; Baroldi P
    Am J Ther; 2015; 22(5):355-60. PubMed ID: 25658956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety profile of tasimelteon, a melatonin MT1 and MT2 receptor agonist: pooled safety analyses from six clinical studies.
    Leger D; Quera-Salva MA; Vecchierini MF; Ogrizek P; Perry CA; Dressman MA
    Expert Opin Drug Saf; 2015; 14(11):1673-85. PubMed ID: 26393492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of Sleep Disturbances Associated with Smith-Magenis Syndrome.
    Kaplan KA; Elsea SH; Potocki L
    CNS Drugs; 2020 Jul; 34(7):723-730. PubMed ID: 32495322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of MElatonin in children with neurodevelopmental disorders and impaired sleep: a randomised, double-blind, placebo-controlled, parallel study (MENDS).
    Appleton RE; Jones AP; Gamble C; Williamson PR; Wiggs L; Montgomery P; Sutcliffe A; Barker C; Gringras P
    Health Technol Assess; 2012; 16(40):i-239. PubMed ID: 23098680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of perampanel in patients with drug-resistant partial seizures after conversion from double-blind placebo to open-label perampanel.
    Montouris G; Yang H; Williams B; Zhou S; Laurenza A; Fain R
    Epilepsy Res; 2015 Aug; 114():131-40. PubMed ID: 26088896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tasimelteon (Hetlioz™): A New Melatonin Receptor Agonist for the Treatment of Non-24-Hour Sleep-Wake Disorder.
    Bonacci JM; Venci JV; Gandhi MA
    J Pharm Pract; 2015 Oct; 28(5):473-8. PubMed ID: 25092604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
    Wolinsky JS; Arnold DL; Brochet B; Hartung HP; Montalban X; Naismith RT; Manfrini M; Overell J; Koendgen H; Sauter A; Bennett I; Hubeaux S; Kappos L; Hauser SL
    Lancet Neurol; 2020 Dec; 19(12):998-1009. PubMed ID: 33129442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Armodafinil for the treatment of excessive sleepiness associated with mild or moderate closed traumatic brain injury: a 12-week, randomized, double-blind study followed by a 12-month open-label extension.
    Menn SJ; Yang R; Lankford A
    J Clin Sleep Med; 2014 Nov; 10(11):1181-91. PubMed ID: 25325609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of a Multi-Layer, Extended-Release Methylphenidate Formulation (PRC-063) on Sleep in Adults with ADHD: A Randomized, Double-Blind, Forced-Dose, Placebo-Controlled Trial Followed by a 6-month Open-Label Extension.
    Weiss MD; Surman C; Khullar A; He E; Cataldo M; Donnelly G
    CNS Drugs; 2021 Jun; 35(6):667-679. PubMed ID: 34057707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.